natgillin/translations-raw huggingface dataset:
In patients with Alzheimer's dementia or dementia due to Parkinson's disease, certain nerve cells die in the brain, resulting in low levels of the neurotransmitter acetylcholine (a substance that allows nerve cells to communicate with each other). 
Pri bolnikih z Alzheimerjevo demenco ali z demenco zaradi Pakinsonove bolezni določene celice v možganih odmrejo, to pa povzroči znižano koncentracijo nevrotransmiterja acetilholina (to je snov, ki omogoča živčnim celicam, da komunicirajo med seboj).
In oral studies with male and female rats, no adverse effects of rivastigmine were observed on fertility or reproductive performance of either the parent generation or the offspring of the parents. 
V študijah peroralnega odmerjanja podganjim samcem in samicam niso opažali nobenega neželenega delovanja rivastigmina na plodnost ali sposobnost razmnoževanja niti pri starševski generaciji niti pri potomcih teh staršev.
Patients with body weight below 50 kg may experience more adverse reactions and may be more likely to discontinue due to adverse reactions. 
Pri bolnikih, ki imajo manj kot 50 kg, je lahko število neželenih učinkov večje, obstaja pa tudi večja verjetnost, da bodo zaradi neželenih učinkov zdravljenje prekinili.
Dementia associated with Parkinson's Disease 
Demenca, povezana s Parkinsonovo boleznijo
Following administration of 14C-rivastigmine, renal elimination was rapid and essentially complete (>90%) within 24 hours. 
C, je bilo ledvično izločanje hitro, saj se je dejansko ves (> 90 %) izločil v 24 urah.
In other cases, rivastigmine has been discontinued (see section 4.8). 
V drugih primerih so rivastigmin ukinili (glejte poglavje 4.8).
In more severe cases nicotinic effects might develop such as muscular weakness, fasciculations, seizures and respiratory arrest with possible fatal outcome. 
V hujših primerih se lahko razvijejo tudi nikotinski učinki, kot so mišična šibkost, fascikulacije, konvulzije in zastoj dihanja, ki se lahko konča tudi s smrtjo.
The most commonly reported adverse reactions (ADRs) are gastrointestinal, including nausea (38%) and vomiting (23%), especially during titration. 
Najpogosteje so poročali o gastrointestinalnih neželenih učinkih, med drugim o navzei (38 %) in bruhanju (23 %), posebno med titriranjem odmerka.
In case of severe vomiting associated with rivastigmine treatment, appropriate dose adjustments as recommended in section 4.2 must be made. 
Če bolnik, ki se zdravi z rivastigminom, bruha, mu je treba ustrezno prilagoditi odmerek zdravila, kot je priporočeno v poglavju 4.2.
The tablets are round and white. 
Tablete so bele in okrogle oblike.
However, due to increased exposure in these populations dosing recommendations to titrate according to individual tolerability should be closely followed as patients with clinically significant renal or hepatic impairment might experience more dose-dependent adverse reactions. 
Vendar se je treba zaradi povečane izpostavljenosti zdravilu pri teh populacijah natančno ravnati po priporočilih, naj se odmerjanje titrira glede na individualno prenašanje, saj je pri bolnikih s klinično pomembno okvaro ledvic ali jeter lahko število od odmerka odvisnih neželenih učinkov večje.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 
Če vam je zdravnik povedal, da da ne prenašate nekaterih sladkorjev, se pred uporabo tega zdravila posvetujte s svojim zdravnikom.
Caution is recommended in treating patients predisposed to such diseases. 
Pri zdravljenju bolnikov, ki so nagnjeni k takim boleznim, je zato potrebna previdnost.
Clinically relevant improvement in these studies was defined a priori as at least 4-point improvement on the ADAS-Cog, improvement on the CIBIC-Plus, or at least a 10% improvement on the PDS. 
Klinično pomembno izboljšanje v teh študijah je bilo pri ADAS-Cog opredeljeno kot izboljšanje za vsaj 4 točke, pri CIBIC-Plus kot izboljšanje, pri PDS pa vsaj kot desetodstotno izboljšanje.
Rivastigmine was not mutagenic in a standard battery of in vitro and in vivo tests, except in a chromosomal aberration test in human peripheral lymphocytes at a dose 10 
V skupini standardnih testov in vitro in in vivo rivastigmin ni bil mutagen, razen v testu kromosomskih aberacij v človeških perifernih levkocitih v odmerku, ki je bil za 10
If treatment is interrupted for more than three days, it should be re-initiated at 1.5 mg twice daily to reduce the possibility of adverse reactions (e.g. vomiting). 
Če zdravljenje prekinemo za več kot tri dni, ga moramo spet začeti z odmerkom 1,5 mg dvakrat na dan, da zmanjšamo možnost neželenih učinkov (na primer bruhanja).
In view of its pharmacodynamic effects and possible additive effects, rivastigmine should not be given concomitantly with other cholinomimetic substances. 
Zaradi farmakodinamičnih učinkov in možnosti aditivnega delovanja se rivastigmina ne sme uporabljati skupaj z drugimi holinomimetičnimi snovmi.
If adverse reactions persist, the daily dose should be temporarily reduced to the previous well-tolerated dose or the treatment may be discontinued. 
Če neželeni učinki vztrajajo, moramo dnevni odmerek začasno zmanjšati na odmerek, ki ga bolnik še dobro prenaša, oziroma prekiniti zdravljenje.
If you have to undergo surgery whilst taking Nimvastid, tell your doctor before you are given any anaesthetics, because Nimvastid may exaggerate the effects of some muscle relaxants during anaesthesia. 
Če jemljete zdravilo Nimvastid in morate na operacijo, povejte zdravniku, da jemljete to zdravilo, preden dobite kakršnokoli anestezijo, saj lahko Nimvastid poveča učinke nekaterih mišičnih relaksantov.
(on carton label only) 
(le na škatli)
Rivastigmine orodispersible tablet is bioequivalent to rivastigmine capsules, with a similar rate and extent of absorption. 
Orodisperzibilna tableta rivastigmina je bioekvivalentna kapsulam rivastigmina ter ima podobno hitrost in obseg absorpcije.
The use of this medicinal product is contraindicated in patients with known hypersensitivity to the active substance rivastigmine, to other carbamate derivatives or to any of the excipients listed in section 6.1. 
Uporaba tega zdravila je kontraindicirana pri bolnikih, ki imajo ugotovljeno preobčutljivost na učinkovino rivastigmin, druge derivate karbamata ali katero koli pomožno snov, navedeno v poglavju
Less than 1% of the administered dose is excreted in the faeces. 
Manj kot 1 % zaužitega odmerka se izloči z blatom.
Patients involved in this study had an MMSE (Mini-Mental State Examination) score of 10-24. 
Bolniki, vključeni v to študijo, so imeli rezultat MMSE (Mini-Mental State Examination - kratek preskus spoznavnih sposobnosti) med 10 in 24.
To be swallowed whole without crushing or opening. 
Kapsulo morate pogoltniti celo, ne da bi jo prej zdrobili ali odprli.
There is no relevant use of Nimvastid in the paediatric population in the treatment of Alzheimer's disease. 
Zdravila Nimvastid ni smiselno uporabljati pri pediatrični populaciji za zdravljenje Alzheimerjeve bolezni.
When normalised to body surface area, the exposure to rivastigmine and its metabolites was approximately equivalent to the maximum recommended human dose of 12 mg/day; however, when compared to the maximum human dose, a multiple of approximately 6-fold was achieved in animals. 
Izpostavljenost rivastigminu in njegovim presnovkom, preračunana na telesno površino, je bila približno enakovredna največjemu priporočenemu odmerku za ljudi, to je 12 mg na dan; v primerjavi z največjim odmerkom za ljudi je bil pri živalih dosežen približno njegov 6-kratni mnogokratnik.
As rivastigmine has a plasma half-life of about 1 hour and a duration of acetylcholinesterase inhibition of about 9 hours, it is recommended that in cases of asymptomatic overdose no further dose of rivastigmine should be administered for the next 24 hours. 
Ker traja plazemski razpolovni čas rivastigmina približno 1 uro, zaviranje acetilholinesteraze pa približno 9 ur, priporočamo, da bolnik 24 ur po morebitnem asimptomatičnem prevelikem odmerku ne jemlje nadaljnjih odmerkov rivastigmina.
The capsules and oral solution can also be used for the treatment of dementia in adult patients with Parkinson's disease. 
Kapsule in orodisperzibilne tablete lahko uporabljamo tudi za zdravljenje demence pri odraslih bolnikih s Parkinsonovo boleznijo.
Rivastigmine 6-12 mg N=473 
Merilo odziva rivastigmin 6-12 mg n = 473
The use of rivastigmine in patients with severe dementia of Alzheimer's disease or associated with Parkinson's disease, other types of dementia or other types of memory impairment (e.g. age-related cognitive decline) has not been investigated and therefore use in these patient populations is not recommended. 
Uporabe rivastigmina pri bolnikih s hudo demenco in Alzheimerjevo boleznijo ali z demenco, povezano s Parkinsonovo boleznijo, z drugimi vrstami demence ali drugimi vrstami spominskih okvar (npr. starostnega kognitivnega upada) niso raziskali, zato ni priporočena.
However, Nimvastid may be used in this patient population and close monitoring is necessary. 
Zdravilo Nimvastid se pri teh bolnikih kljub temu lahko uporabi, potrebno pa je natančno spremljanje zdravljenja.
Symptomatic treatment of mild to moderately severe Alzheimer's dementia. 
Simptomatsko zdravljenje blage do zmerno hude Alzheimerjeve demence.
What Nimvastid is and what it is used for What you need to know before you take Nimvastid How to take Nimvastid 
Kaj je zdravilo Nimvastid in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Nimvastid Kako jemati zdravilo Nimvastid Možni neželeni učinki
Rivastigmine should be administered twice a day, with morning and evening meals. 
Bolnik mora rivastigmin jemati dvakrat na dan, z jutranjim in večernim obrokom.
Motor dysfunction 
Motorične motnje
The secondary definition of response required a 4-point or greater improvement on the ADAS-Cog, no worsening on the CIBIC-Plus, and no worsening on the PDS. 
Sekundarna opredelitev odziva je zahtevala izboljšanje pri ADAS-Cog za najmanj 4 točke in nobenega poslabšanja pri CIBIC-Plus in PDS.
ADCS-CGIC Rivastigmine 
ADCS-CGIC rivastigmin
As a consequence of rivastigmine's interaction with its target enzyme, the increase in bioavailability is about 1.5-fold greater than that expected from the increase in dose. 
Posledica medsebojnega delovanja rivastigmina in tarčnega encima je povečanje biološke uporabnosti, ki je za 1,5-krat večja, kot bi pričakovali glede na povečanje odmerka.
Put the tablet on the tongue as soon as it is removed from the packaging. 
Tableto položite na jezik, takoj ko jo stresete iz ovitka.
Adverse reactions in Table 1 and Table 2 are listed according to MedDRA system organ class and frequency category. 
V preglednici 1 in preglednici 2 so neželeni učinki navedeni glede na organski sistem po MedDRA klasifikaciji in glede na kategorijo pogostnosti.
No safety margins to human exposure were achieved in the animal studies due to the sensitivity of the animal models used. 
V študijah na živalih zaradi občutljivosti uporabljenih živalskih modelov ni bilo mogoče ugotoviti varnega območja za dajanje zdravila ljudem.
Rivastigmine orodispersible tablets may be used as an alternative to rivastigmine capsules. 
Orodisperzibilne tablete rivastigmina se lahko predpisujejo kot alternativa kapsulam rivastigmina.
In these cases, treatment should be discontinued (see section 4.3). 
V opisanih primerih je treba zdravljenje prekiniti (glejte poglavje 4.3).
Table 3 lists the number and percentage of patients from the specific 24-week clinical study conducted with rivastigmine in patients with dementia associated with Parkinson's disease with pre-defined adverse events that may reflect worsening of parkinsonian symptoms. 
Preglednica 3 navaja število (n) in odstotek bolnikov iz specifične 24-tedenske klinične študije z rivastigminom pri bolnikih z demenco, povezano s Parkinsonovo boleznijo, z vnaprej opredeljenimi neželenimi dogodki, ki lahko odražajo poslabšanje simptomov Parkinsonove bolezni.
You should not breast-feed during treatment with Nimvastid. 
Med zdravljenjem z zdravilom Nimvastid ne smete dojiti.
ADAS-Cog: improvement of at least 4 points CIBIC-Plus: improvement PDS: improvement of at least 10% 
CIBIC-Plus: izboljšanje PDS: izboljšanje za najmanj 10 %
Similarly a larger treatment effect was observed in those patients with visual hallucinations (see Table 6). 
Boljši učinek so opazili tudi pri tistih bolnikih z vidnimi halucinacijami (glejte preglednico 6).
The following adverse reactions, listed below in Table 1, have been accumulated in patients with Alzheimer's dementia treated with rivastigmine. 
Neželene učinke, navedene v spodnji preglednici 1, so zbrali pri bolnikih z Alzheimerjevo demenco, zdravljenih z rivastigminom.
Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease. 
Simptomatsko zdravljenje blage do zmerno hude demence pri bolnikih z idiopatsko Parkinsonovo boleznijo.
Date of first authorisation: 11/5/2009 Date of latest renewal: DD month YYYY 
Datum prve odobritve: 11. maj 2009 Datum zadnjega podaljšanja: 16. januar 2014
No adverse effects of rivastigmine were observed on fertility or reproductive performance in rats (see section 5.3). 
Pri podganah niso opažali neželenih učinkov na plodnost in sposobnost razmnoževanja (glejte poglavje 5.3).
Care must be taken when using rivastigmine in patients with sick sinus syndrome or conduction defects (sino-atrial block, atrio-ventricular block) (see section 4.8). 
Previdnost je potrebna pri uporabi rivastigmina pri bolnikih s sindromom bolnega sinusnega vozla ali s prevodnimi motnjami (sinuatrialni blok, atrioventrikularni blok) (glejte poglavje 4.8).
Similarly a larger effect was observed in Parkinson's disease patients with visual hallucinations (see section 5.1). 
Opazili so ga tudi pri tistih bolnikih s Parkinsonovo boleznijo, ki so imeli vidne halucinacije (glejte poglavje 5.1).
Additionally there have been post-marketing cases of dizziness, tremor, headache, somnolence, confusional state, hypertension, hallucinations and malaise. 
Poleg tega je v času trženja zdravila prišlo do primerov omotičnosti, tremorja, glavobola, somnolence, stanja zmedenosti, hipertenzije, halucinacij in splošnega slabega počutja.
Possible dose adjustments or temporarily stopping treatment can be considered if needed. 
Razmisliti je treba o morebitni spremembi odmerka ali začasni prekinitvi zdravljenja.
These include the ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, a performance based measure of cognition), the CIBIC-Plus (Clinician's Interview Based Impression of Change-Plus, a comprehensive global assessment of the patient by the physician incorporating caregiver input), and the PDS (Progressive Deterioration Scale, a caregiver-rated assessment of the activities of daily living including personal hygiene, feeding, dressing, household chores such as shopping, retention of ability to orient oneself to surroundings as well as involvement in activities relating to finances, etc.). 
Med njimi so ADAS-Cog (Alzheimer's Disease Assessment Scale - Cognitive subscale, Lestvica za oceno kognitivnih sposobnosti bolnikov z Alzheimerjevo boleznijo, merilo za kognicijo, ki temelji na storilnosti), CIBIC-Plus (Clinician's Interview Based Impression of Change-Plus, Zdravnikova ocena spremembe bolezni na podlagi pogovora, celostno globalno ocenjevanje bolnika, ki ga opravlja zdravnik in ki zajema tudi podatke, ki jih daje/-jo negovalec/-ci) in PDS (Progressive Deterioration Scale, Lestvica progresivnega slabšanja, negovalčeva ocena vsakodnevnih aktivnosti, na primer osebne higiene, hranjenja, oblačenja, gospodinjskih opravil, na primer nakupovanja, ohranjanje zmožnosti orientacije v okolju, pa tudi ukvarjanje z denarnimi zadevami itn.).
Based on in vitro studies, no pharmacokinetic interaction is expected with medicinal products metabolised by the following cytochromes isoemzymes: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8, CYP2C19, or CYP2B6. 
Po podatkih raziskav in vitro ni pričakovati farmakokinetičnih interakcij z zdravili, ki jih presnavljajo naslednji izoencimi s citokromi: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8, CYP2C19 in CYP2B6.
Patients who show signs or symptoms of dehydration resulting from prolonged vomiting or diarrhoea can be managed with intravenous fluids and dose reduction or discontinuation if recognised and treated promptly. 
Bolnike z znaki ali simptomi dehidracije zaradi dolgotrajnega bruhanja ali driske je v primeru prepoznavanja stanja in takojšnjega ukrepanja mogoče zdraviti z intravenskim nadomeščanjem tekočin in zmanjšanjem odmerka ali prekinitvijo odmerjanja.
Pre-defined adverse events that may reflect worsening of parkinsonian symptoms in patients with dementia associated with Parkinson's disease 
Vnaprej opredeljeni neželeni dogodki, ki lahko odražajo poslabšanje simptomov Parkinsonove bolezni pri bolnikih z demenco, povezano s Parkinsonovo boleznijo
Caution is recommended when selecting anaesthetic agents. 
Pri izbiri anestetika se priporoča previdnost.
Taking the two medicines together could cause problems such as stiff limbs and trembling hands. 
Sočasno jemanje obeh navedenih zdravil lahko povzroči težave, kot sta okorelost okončin in tresenje rok.
Uncommon (may affect up to 1 in 100 people) • Hyperactivity (high level of activity, restlessness) 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) - hiperaktivnost (povečana stopnja aktivnosti, nemir)
Table 2 shows the adverse reactions reported during clinical studies conducted in patients with dementia associated with Parkinson's disease treated with rivastigmine capsules. 
V preglednici 2 so navedeni neželeni učinki, o katerih so poročali iz kliničnih študij, ki so jih izvajali pri bolnikih z demenco, povezano s Parkinsonovo boleznijo, ki so se zdravili s kapsulami rivastigmina.
Although a treatment effect was demonstrated in the overall study population, the data suggested that a larger treatment effect relative to placebo was seen in the subgroup of patients with moderate dementia associated with Parkinson's disease. 
Čeprav se je terapevtski učinek pokazal pri vseh bolnikih, ki so bili vključeni v študijo, podatki kažejo, da so boljši terapevtski učinek v primerjavi s placebom opazili pri podskupini bolnikov z zmerno demenco in s Parkinsonovo boleznijo.
The Cmax of rivastigmine was approximately 60% higher and the AUC of rivastigmine was more than twice as high in subjects with mild to moderate hepatic impairment than in healthy subjects. 
Cmax rivastigmina je bila za približno 60 % večja, AUC rivastigmina pa več kot dvakrat večja pri osebah z blago do zmerno jetrno okvaro kot pri zdravih osebah.
Parkinsonism 
Parkinsonizem
Cholinesterase inhibitors should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease. 
Previdnost je potrebna tudi pri predpisovanju zaviralcev holinesteraze bolnikom z anamnezo astme ali obstruktivne pljučne bolezni.
By blocking these enzymes, Nimvastid allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's disease and dementia associated with Parkinson's disease. 
Zdravilo Nimvastid z zaviranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni in demence v povezavi s Parkinsonovo boleznijo.
If you accidentally take more Nimvastid than you should, inform your doctor. 
Če ste vzeli večji odmerek zdravila Nimvastid, kot bi smeli Če nehote vzamete več zdravila Nimvastid, kot bi smeli, obvestite svojega zdravnika.
According to its metabolism, metabolic interactions with other medicinal products appear unlikely, although rivastigmine may inhibit the butyrylcholinesterase mediated metabolism of other substances. 
Glede na presnovo rivastigmina se zdi medsebojno delovanje z drugimi zdravili malo verjetno, čeprav lahko rivastigmin zavre presnovo drugih učinkovin, v katero je vključena butirilholinesteraza.
Gastrointestinal disorders such as nausea, vomiting and diarrhoea are dose-related, and may occur particularly when initiating treatment and/or increasing the dose (see section 4.8). 
Prebavne motnje, na primer navzea, bruhanje in driska, so povezane z velikostjo odmerka in se lahko pojavijo zlasti na začetku zdravljenja in/ali ob povečanju odmerka (glejte poglavje 4.8).
No evidence of carcinogenicity was found in studies in mice and rats at the maximum tolerated dose, although the exposure to rivastigmine and its metabolites was lower than the human exposure. 
V študijah na miših in podganah pri največjem odmerku, ki so ga živali še prenašale, niso opazili nobenih znakov kancerogenosti; vendar je bila izpostavljenost rivastigminu in njegovim presnovkom manjša od izpostavljenosti pri ljudeh.
Cmax and AUC of rivastigmine were more than twice as high in subjects with moderate renal impairment compared with healthy subjects; however there were no changes in Cmax and AUC of rivastigmine in subjects with severe renal impairment. 
Cmax in AUC rivastigmina sta bili pri osebah z zmerno ledvično okvaro več kot dvakrat večji kot pri zdravih osebah, pri osebah s hudo ledvično okvaro pa ni bilo sprememb.
HDPE container: boxes of 200 or 250 hard capsules are available. 
Vsebnik (HDPE): na voljo so škatle po 200 ali 250 trdih kapsul.
Other side effects seen with rivastigmine transdermal patches and which may occur with the orodispersible tablets: 
Drugi neželeni učinki, ki so jih opažali pri uporabi rivastigmin transdermalnih obližev in bi se lahko pojavili tudi pri uporabi orodisperzibilnih tablet:
HDPE container: 200 or 250 hard capsules in a box. 
Vsebnik (HDPE): 200 ali 250 trdih kapsul, v škatli.
ITT: Intent-To-Treat; RDO: Retrieved Drop Outs 
RDO (Retrieved Drop Outs) - upoštevani izpadli primeri
There have been rare post-marketing reports of patients experiencing allergic dermatitis (disseminated) when administered rivastigmine irrespective of the route of administration (oral, transdermal). 
V redkih poročilih iz obdobja po prihodu zdravila na trg so opisovali bolnike, pri katerih je pri aplikaciji rivastigmina prišlo do alergijskega dermatitisa (diseminirane oblike) ne glede na način vnosa zdravila (peroralno ali transdermalno).
• Do not open or crush the capsules. 
- Kapsul ne odpirajte in ne drobite.
As a cholinesterase inhibitor, rivastigmine may exaggerate the effects of succinylcholine-type muscle relaxants during anaesthesia. 
Ker je rivastigmin zaviralec holinesteraze, lahko med anestezijo zelo poveča učinke mišičnih relaksantov tipa sukcinilholina.
Cardiovascular betablockers are expected to be associated with the greatest risk, but reports have also been received in patients using other beta-blockers. 
Z največjim tveganjem naj bi bili povezani tisti antagonisti adrenergičnih receptorjev beta, ki delujejo na kardiovaskularni sistem, vendar so o težavah poročali tudi pri bolnikih, ki so uporabljali druge antagoniste adrenergičnih receptorjev beta.
The patients studied had an MMSE (Mini-Mental State Examination) score of 10-24. 
Pri proučevanih bolnikih so bili rezultati MMSE (Mini-Mental State Examination - kratek preskus spoznavnih sposobnosti) med 10 in 24.
Patients with clinically significant renal or hepatic impairment might experience more adverse reactions (see sections 4.2 and 5.2). 
Pri bolnikih s klinično pomembno ledvično ali jetrno okvaro je lahko število neželenih učinkov večje (glejte poglavji 4.2 in 5.2).
In healthy young men, an oral 3 mg dose decreases acetylcholinesterase (AChE) activity in CSF by approximately 40% within the first 1.5 hours after administration. 
Pri zdravih mladih moških 3-miligramski peroralni odmerek v poldrugi uri po zaužitju zmanjša aktivnost AChE v cerebrospinalni tekočini (CSF) za približno 40 %.
The recommended maximum daily dose is 6 mg twice a day. 
Priporočeni največji dnevni odmerek je 6 mg dvakrat na dan.